ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Imokawa, S
Right arrow Articles by Helmers, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Imokawa, S
Right arrow Articles by Helmers, R.
Eur Respir J 2000; 15: 373-381
Copyright © ERS Journals Ltd 2000

Original Articles

Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients

S Imokawa, TV Colby, KO Leslie, and RA Helmers

Pneumonitis is a serious and unpredictable side-effect of treatment with methotrexate (MTX) that may become life-threatening. The clinical and histological features of nine cases of MTX pneumonitis are reported and the literature reviewed. The typical clinical symptoms include progressive shortness of breath and cough, often associated with fever. Hypoxaemia and tachypnoea are always present and crackles are frequently audible. Chest radiography reveals a diffuse interstitial or mixed interstitial and alveolar infiltrate, with a predilection for the lower lung fields. Pulmonary function tests show a restrictive pattern with diminished diffusion capacity. Lung biopsy reveals cellular interstitial infiltrates, granulomas or a diffuse alveolar damage pattern accompanied by perivascular inflammation. These clinical and pathological findings are not specific to MTX pneumonitis and can be seen with other drug-induced lung toxicities. It is important that all patients receiving methotrexate be educated concerning this potential adverse reaction and instructed to contact their physicians should significant new pulmonary symptoms develop while undergoing therapy. If methotrexate pneumonitis is suspected, methotrexate should be discontinued, supportive measures instituted and careful examination for different causes of respiratory distress conducted.


This article has been cited by other articles:


Home page
 INT J SURG PATHOLHome page
A. Cavazza, S. Harari, A. Caminati, M. Barbareschi, C. Carbonelli, L. Spaggiari, M. Paci, and G. Rossi
The Histology of Pulmonary Sarcoidosis: A Review with Particular Emphasis on Unusual and Underrecognized Features
International Journal of Surgical Pathology, June 1, 2009; 17(3): 219 - 230.
[Abstract] [PDF]

Home page
 ACCP Pulmonary Med Brd RevHome page
D. W. Kamp
Drug-Induced Lung Diseases
ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 319 - 344.
[Full Text] [PDF]

Home page
 ChestHome page
J. J. Swigris, A. Fischer, J. Gilles, R. T. Meehan, and K. K. Brown
Pulmonary and Thrombotic Manifestations of Systemic Lupus Erythematosus
Chest, January 1, 2008; 133(1): 271 - 280.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
K. Collins, H. Aspey, A. Todd, V. Saravanan, M. Rynne, and C. Kelly
Methotrexate pneumonitis precipitated by switching from oral to parenteral administration
Rheumatology, January 1, 2008; 47(1): 109 - 110.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
V. Saravanan and C. Kelly
Drug-related pulmonary problems in patients with rheumatoid arthritis
Rheumatology, July 1, 2006; 45(7): 787 - 789.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. J. Kinder, A. B. Hassell, J. Brand, A. Brownfield, M. Grove, and M. F. Shadforth
The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions
Rheumatology, January 1, 2005; 44(1): 61 - 66.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
V. Saravanan and C. A. Kelly
Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis
Rheumatology, February 1, 2004; 43(2): 143 - 147.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. J. K. Ostor, D. R. O'Gradaigh, and J. R. Jenner
Methotrexate for rheumatoid arthritis: what should the patient be told?
Rheumatology, December 1, 2003; 42(12): 1576 - 1578.
[Full Text] [PDF]

Home page
 ChestHome page
S. Abi-Nassif, E. J. Mark, R. B. Fogel, and R. K. Hallisey Jr
Pegylated Interferon and Ribavirin-Induced Interstitial Pneumonitis With ARDS
Chest, July 1, 2003; 124(1): 406 - 410.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. A. Schlesinger and J. W. Leatherman
Rheumatology
Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1161 - 1165.
[Full Text] [PDF]

Home page
 ChestHome page
E. Azoulay, H. Attalah, A. Harf, B. Schlemmer, and C. Delclaux
Granulocyte Colony-Stimulating Factor or Neutrophil-Induced Pulmonary Toxicity: Myth or Reality? : Systematic Review of Clinical Case Reports and Experimental Data
Chest, November 1, 2001; 120(5): 1695 - 1701.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. FUHRMAN, A. PARROT, M. WISLEZ, H. PRIGENT, V. BOUSSAUD, J.-F. BERNAUDIN, C. MAYAUD, and J. CADRANEL
Spectrum of CD4 to CD8 T-Cell Ratios in Lymphocytic Alveolitis Associated with Methotrexate-induced Pneumonitis
Am. J. Respir. Crit. Care Med., October 1, 2001; 164(7): 1186 - 1191.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
Ph. Camus, P. Foucher, Ph. Bonniaud, and K. Ask
Drug-induced infiltrative lung disease
Eur. Respir. J., July 1, 2001; 18(32_suppl): 93S - 100s.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the European Respiratory Society.